Clinical Trials Browser

Phase 1/2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 4-fluorobenzoyl-TN-14003 × Clear all

NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive